{"id":"NCT03036813","sponsor":"Pfizer","briefTitle":"Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)","officialTitle":"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2019-10-08","completion":"2019-10-08","firstPosted":"2017-01-30","resultsPosted":"2021-01-07","lastUpdate":"2023-07-27"},"enrollment":449,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Sickle Cell Disease"],"interventions":[{"type":"DRUG","name":"voxelotor","otherNames":["GBT440"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dose 1","type":"ACTIVE_COMPARATOR"},{"label":"Dose 2","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease","primaryOutcome":{"measure":"Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Voxelotor 900 mg","deltaMin":30,"sd":null},{"arm":"Voxelotor 1500 mg","deltaMin":46,"sd":null},{"arm":"Placebo","deltaMin":6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":62,"countries":["United States","Canada","Egypt","France","Italy","Jamaica","Kenya","Lebanon","Netherlands","Oman","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["33838113","33476432","31199090","28337324"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=GBT440-031"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":92},"commonTop":["Headache","Pain in extremity","Pain","Diarrhoea","Upper respiratory tract infection"]}}